Invasive cervical cancer remains an important global cause of death, despite the declining
prevalence within the United States. Definitive therapies, including surgical resection of …

Background GOG 240 was a practice-changing randomised phase 3 trial that concluded that
chemotherapy plus bevacizumab for advanced cervical cancer significantly improves overall …

Precision medicine for cervical cancer : Current Opinion in Obstetrics and Gynecology
Precision medicine for cervical cancer : Current Opinion in Obstetrics and Gynecology Log …

Cervical cancer accounts for most deaths due to cancer in women, majorly in developing
nations. The culprit behind this disease is the human papillomavirus (HPV) which accounts …

Cervical cancer (CC) is the second most common cancer worldwide, strongly linked to high-
risk human papilloma virus infection. Although screening programs have led to a relevant …

The management of locally advanced cervix cancer has undergone a paradigm shift during
the last decade. Concurrent chemoradiation (CCRT)(with cisplatin alone or in combination) …

Objective Despite advances in cervical cancer prevention and diagnosis, outcomes for
patients given a diagnosis of advanced and recurrent disease are poor. In the GOG240 trial …

Cervical cancer is the second major cause of death in women. In locally-advanced or
refractory cervical cancer, cisplatin-based chemotherapy still represents the best chance of …

The introduction of concurrent chemotherapy and radiotherapy for the definitive treatment of
cervical cancer constituted a major advance in the management of cervical cancer, resulting …

Despite availability of primary and secondary prevention measures, cervical cancer persists
as one of the most common cancers among women around the world. Although early-stage …